In this study, we therefore hypothesized that MET activation may lead to lapatinib resistance in HER2-driven esophageal adenocarcinoma, and tested the feasibility of MET targeting by small-molecule inhibitor Foretinib in EAC cells. This evidence concerns the gene MET and esophageal adenocarcinoma.